SLGL News and Press, Sol-Gel Technologies Ltd. From 12/30/19

All co-primary endpoints achieved in both Phase 3 clinical trials Twyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over time Additional data to be shared during the January 8 th investor conference call and webcast NESS...

Sol-Gel Technologies (NASDAQ: SLGL ): Q3 GAAP EPS of -$0.37 misses by $0.14 . More news on: Sol-Gel Technologies Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Top-line generic product revenue of $4.7 million in the third quarter Results from TWIN Phase 3 trials in acne vulgaris remain on track for the fourth quarter of 2019 NESS ZIONA, Israel, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage ...

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation technology in treating papulopustular rosacea, including Phase 3 results for Epsolay ® microencapsu...

Sol-Gel Technologies (NASDAQ: SLGL ): Q2 GAAP EPS of -$0.26 beats by $0.02 . More news on: Sol-Gel Technologies Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Top-line generic product revenue of $7.8 million TWIN Phase 3 trials are fully enrolled and remain on track to report results in 4Q19 NESS ZIONA, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on ide...

NESS ZIONA, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel” or the “Company”),  a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug produc...

Notice of allowance for U.S. patent application extends TWIN patent protection to 2038 Clinical study for SGT-210 in palmoplantar keratoderma (PPK) intended to begin in early 2020 Webcast of Analyst & Investor Day today at 8:30 a.m. ET NESS ZIONA, Israel, July 25, 2019 (GLO...

Gainers:  Taronis Technologies (NASDAQ: TRNX ) +68% . Nuverra Environmental Solutions (NYSEMKT: NES ) +40% . Soliton (NASDAQ: SOLY ) +31% . Oasmia Pharmaceutical (NASDAQ: OASM ) +24% . Xenetic Biosciences (NASDAQ: XBIO ) +15% . BIOLASE (NASDAQ: BIOL ) +14% . Sol-Gel Technologies...

Ultra-thinly traded micro cap Sol-Gel Technologies ( SLGL +13.1% ) is up on almost a 19x surge in volume, albeit on turnover of only 267K shares, in response to positive results from two Phase 3 clinical trials, SGT 54-01 and SGT 54-02 , evaluating Epsolay microencapsulated benzoyl pe...